Isokinetic Fatigue Index in a Population of Triathletes (ISOTRIFA)

Pilot Study to Evaluate an Isokinetic Fatigue Index for Prevention Purposes in a Population of Triathletes

The aim of this study is to evaluate the relevance of carrying out a measure of muscular fatigability by isokinetism, in the search for factors favouring micro-traumatic lesions of the lower limbs in a population of triathletes.

This is a prospective monocentric pilot study of the before/after type in which the patient is his or her own control, in high-level triathletes practising an endurance sport, who have had more than 7 consecutive days off running due to a musculoskeletal injury during the previous sporting year.

Study Overview

• Status: Recruiting
• Conditions: Musculoskeletal Diseases
• Intervention / Treatment: Diagnostic test: isokinetism test

• Study Type: Interventional
• Enrollment (Anticipated): 25
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Guillaume BERTOUX; Phone Number: + 33 3 21 99 87 13; Email: g.bertoux@ch-boulogne.fr
• Study Contact Backup: Name: Yoann MORVAN; Phone Number: + 33 3 21 99 33 85; Email: y.morvan@ch-boulogne.fr

Study Locations

• France
  • Boulogne-sur-Mer, France, 62200
    • Recruiting
    • Boulogne sur Mer Hospital Center
    • Principal Investigator: Yoann MORVAN
    • Contact: Justine MONVOISIN; Phone Number: + 33 3 21 99 34 40; Email: j.monvoisin@ch-boulogne.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Having had a practical running break of more than 7 consecutive days due to a musculoskeletal injury of a lower limb during the previous sport year
• Willing to comply with all study procedures
• Having given written consent
• Socially insured

Exclusion Criteria:

• Pain that does not allow an isokinetic test to be performed
• Knee joint amplitude less than 100° of flexion or flessum greater than 5°.
• History of rupture or ligamentoplasty of the anterior cruciate ligament less than 2 years ago
• History of knee surgery less than 2 years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: isokinetism test in high level triathletes practicing an endurance sport	Diagnostic test: isokinetism test; measure of muscular fatigability by isokinetism

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
fatigue index between the injured leg and the healthy leg	To compare the fatigue index between the injured leg and the healthy leg in high level triathletes injured in the previous season.	the day of inclusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
difference of the fatigue index to the difference of the Croisier ratio between the injured leg and the healthy leg	Correlate the difference in the fatigue index to the difference in the Croisier ratio between the injured leg and the healthy leg.	the day of inclusion

Collaborators and Investigators

• Sponsor: Boulogne sur Mer Hospital Center

Study record dates

Study Major Dates

• Study Start (Actual): November 14, 2022
• Primary Completion (Anticipated): November 14, 2024
• Study Completion (Anticipated): November 14, 2024

Study Registration Dates

• First Submitted: November 15, 2022
• First Submitted That Met QC Criteria: November 30, 2022
• First Posted (Actual): December 2, 2022

Study Record Updates

• Last Update Posted (Actual): December 2, 2022
• Last Update Submitted That Met QC Criteria: November 30, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Musculoskeletal Diseases
• Other Study ID Numbers: 2022-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No